Business, energy, technology, markets and global industry news from Business News Today

National Comprehensive Cancer Network

PharmaDeviceNews National Comprehensive Cancer Network
Natera’s Signatera blood-based MRD test showed higher sensitivity than AMERK in predicting Merkel cell carcinoma recurrence, according to a JAMA Dermatology study. Representative image.
Pharma & Biotech

Signatera detected 90% of recurrences versus 55% for AMERK. Is Merkel cell surveillance about to change?

Signatera showed 90% sensitivity versus 55% for AMERK in Merkel cell carcinoma, strengthening Natera’s case for broader MRD surveillance.

Read More
Pharma & Biotech

ESMO-EURACAN adds CHEMOSAT to uveal melanoma guidance as Delcath Systems strengthens clinical position

Delcath Systems won ESMO-EURACAN guideline recognition for CHEMOSAT in uveal melanoma. Read what this could change for liver-directed cancer care.

Read More